Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + arginine is a fixed-dose combination of the non-steroidal anti-inflammatory drug (NSAID) ibuprofen and the amino acid L-arginine. Ibuprofen acts as a non-selective inhibitor of the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are essential for the biosynthesis of prostaglandins that mediate pain, inflammation, and fever. The inclusion of arginine in the formulation creates a highly soluble salt (ibuprofen arginate), which facilitates more rapid absorption from the gastrointestinal tract compared to standard ibuprofen formulations, thereby providing a faster onset of analgesic relief. In clinical research conducted by Samsung Medical Center, this combination was evaluated for its effectiveness in treating muscle and joint pain in women during the menopausal transition (perimenopause), comparing its efficacy against oral contraceptives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + arginine.